Sagimet Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Sagimet Biosciences has a total shareholder equity of $170.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $174.8M and $4.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$152.49m |
| Equity | US$170.68m |
| Total liabilities | US$4.09m |
| Total assets | US$174.78m |
Recent financial health updates
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Dec 15
Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31Recent updates
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Dec 15Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 31Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Apr 26Sagimet: Additional Upside Possible After Latest NASH Data Release
Jan 24Financial Position Analysis
Short Term Liabilities: SGMT's short term assets ($157.2M) exceed its short term liabilities ($4.1M).
Long Term Liabilities: SGMT has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SGMT is debt free.
Reducing Debt: SGMT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SGMT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SGMT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 18.2% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 05:29 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sagimet Biosciences Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrea Tan | Goldman Sachs |
| Andrea Newkirk | Goldman Sachs |
| Antonio Arce | H.C. Wainwright & Co. |